Pharmaceuticals News and Research

RSS

Breakthrough discovery could help young girls suffering from rare form of epilepsy

An international team, led by a University of Adelaide genetics expert, has made a breakthrough discovery which is expected to help thousands of young girls worldwide who are suffering from a rare yet debilitating form of epilepsy.

7 Jul 2015

Celtaxsys receives FDA clearance to begin acebilustat Phase 2 trial in adult CF patients in the US

Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with rare and orphan inflammatory disease indications, announced today that it has gained clearance from the U.S. Food and Drug Administration to begin a Phase 2 clinical trial of its flagship drug candidate, acebilustat (CTX-4430), in adult CF patients in the US.

7 Jul 2015

Allergan enters into agreement to acquire Oculeve

Allergan plc, a leading global pharmaceutical company, and Oculeve, a development-stage medical device company focused on developing novel treatments for dry eye disease, today announced that they have entered into an agreement under which Allergan will acquire Oculeve in an all-cash transaction.

6 Jul 2015

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS).

6 Jul 2015

Redwood Pharma signs licensing agreement with Broda Technologies for hydrogel drug delivery technology

Redwood Pharma AB has entered into a licensing agreement with Broda Technologies Co., Ltd., operating in both the US and China, to use the company's proprietary IntelliGel supramolecular hydrogel technology in its lead chronic Dry Eye therapeutic currently under development and other ophthalmic therapies.

3 Jul 2015

NDSU's Stephen O'Rourke awarded NIH grant to conduct cardiovascular research

Stephen O'Rourke, professor of pharmaceutical sciences at North Dakota State University, Fargo, has received a $435,000 grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to conduct cardiovascular research.

3 Jul 2015

European Nanomedicine Characterization Lab aims to bring safe, efficient nano-therapeutics to patients

Empa, the Swiss Federal Laboratories for Materials Science and Technology, is part of the European Nanomedicine Characterization Laboratory, a European project funded by the EU framework program «Horizon 2020.

2 Jul 2015

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active.

2 Jul 2015

Study demonstrates the important role of placebo effect in medical care

The "placebo effect" is often described as events that occur when patients show improvement from treatments that contain no active ingredients.

2 Jul 2015

BiondVax Pharmaceuticals intends to close trading on NASDAQ market on July 10, 2015

BiondVax Pharmaceuticals Ltd. today announced that it will be closing trading on the NASDAQ market on Friday, July 10, 2015, in celebration of its recent initial public offering in the United States and the launch of its international investor relations program.

2 Jul 2015

Results from Phase 3 study evaluating safety and efficacy of Zalviso published in Anesthesiology

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that results from the IAP311 study have been published in Anesthesiology.

2 Jul 2015

NDSU researcher awarded $1.35 million research grant to develop targeted treatment for colorectal cancer

A researcher at North Dakota State University, Fargo, is receiving a four-year $1.35 million research project grant from the National Cancer Institute of the National Institutes of Health to develop a targeted treatment for colorectal cancer.

2 Jul 2015

Adis launches new platform to make drug information more accessible

Adis, a leading global provider of drug information, has taken a major step forward in its quest to make expertly written drug information more accessible, with the launch of a new platform AdisInsight. The platform presents a unique, joined-up view of current evidence on drug treatments being developed worldwide - how well they work, how safe they are, who is working on them, and how soon they will be available - in a single database.

2 Jul 2015

Domainex’s new integrated bioassay service platform accelerates progression of drug discovery projects

Domainex Ltd, a private drug discovery service company, today announces that it is launching an integrated bioassay service platform, BioassayBuilder.

2 Jul 2015

Concert Pharmaceuticals’ precision deuteration platform can enhance metabolic properties of drugs

Substituting deuterium for certain hydrogen atoms in molecules has been shown to enhance the metabolic properties of a number of drugs and provides a promising approach to the discovery and development of innovative drug products.

2 Jul 2015

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of groundbreaking drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), announced today that Robert G. Miller, M.D., Director of the Forbes Norris MDA/ALS Research Center at Sutter Health's California Pacific Medical Center in San Francisco, has been awarded a grant from The ALS Association for $1.5 million to help fund a Phase 2 clinical study of the company's investigational therapy for ALS, NP001.

1 Jul 2015

ALS ACT initiative to speed discovery of new ALS treatments

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) initiative.

1 Jul 2015

Implantable microfluid system can efficiently stabilize intraocular pressure

Elevated or diminished eye pressure impairs our ability to see, and in the worst cases, can even lead to blindness. Until now, there has been no effective long-term treatment. In response, Fraunhofer researchers are developing an implantable microfluid system that can efficiently and durably stabilize intraocular pressure.

1 Jul 2015

Genpact, UCB receive Aecus Innovation Award for collaboration in driving global business services

UCB, a multinational biopharmaceutical company, and Genpact, a global leader in designing, transforming, and running intelligent business operations, have received the Aecus Innovation Award in recognition of their close collaboration in driving transformation that achieved far-reaching operational efficiencies in UCB's global business services (GBS) finance organization.

1 Jul 2015

R-Japan receives license for cell processing facility

R-Japan Co.,Ltd. obtained the license of cell processing facility under the Act on the Safety of Regenerative Medicine from the Ministry of Health, Labour and Welfare Kinki Bureau of Health and Welfare on June 29, 2015.

1 Jul 2015

Pharmaceuticals News and Research

Breakthrough discovery could help young girls suffering from rare form of epilepsy

Celtaxsys receives FDA clearance to begin acebilustat Phase 2 trial in adult CF patients in the US

Allergan enters into agreement to acquire Oculeve

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Redwood Pharma signs licensing agreement with Broda Technologies for hydrogel drug delivery technology

NDSU's Stephen O'Rourke awarded NIH grant to conduct cardiovascular research

European Nanomedicine Characterization Lab aims to bring safe, efficient nano-therapeutics to patients

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Study demonstrates the important role of placebo effect in medical care

BiondVax Pharmaceuticals intends to close trading on NASDAQ market on July 10, 2015

Results from Phase 3 study evaluating safety and efficacy of Zalviso published in Anesthesiology

NDSU researcher awarded $1.35 million research grant to develop targeted treatment for colorectal cancer

Adis launches new platform to make drug information more accessible

Domainex’s new integrated bioassay service platform accelerates progression of drug discovery projects

Concert Pharmaceuticals’ precision deuteration platform can enhance metabolic properties of drugs

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

ALS ACT initiative to speed discovery of new ALS treatments

Implantable microfluid system can efficiently stabilize intraocular pressure

Genpact, UCB receive Aecus Innovation Award for collaboration in driving global business services

R-Japan receives license for cell processing facility

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring